Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration

<p class="Abstract">It was aimed to explore the expression level of miRNA-486 and miRNA-499 in the plasma of lung cancer patients and analysis their differences in expre-ssion. The expression level of both miRNA-486 and miRNA-499 in the plasma of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) were lower than that of the control group (p<0.05) and the decrease was more obvious in NSCLC. Compare with the miRNA-499，expression quantity in NSCLC patients plasma. There was statistical significance difference (p<0.05) between III～Ⅳstage and I～II stage. The expression quantity of miRNA in plasma of patients with extensive-stage SCLC was lower than that of patients with limited-stage SCLC (p<0.05). The sensitivity and specificity of plasms miRNA-486 respectively were 88.5% and 83.3%. The expression of miRNA-499 and miRNA-486 in lung cancer patients were up-regulated, and might be closely related to the occurrence and prognosis of lung cancer, and might be used as potential screening and prognosis index for lung cancer.</p><p> </p>

Download Full-text

Expression analysis of three miRNAs, miR-26a, miR-29b and miR-519d, in relation to MMP-2 expression level in non-small cell lung cancer patients: a pilot study

Medical Oncology ◽

10.1007/s12032-016-0815-z ◽

2016 ◽

Vol 33 (8) ◽

Cited By ~ 12

Author(s):

D. Pastuszak-Lewandoska ◽

J. Kordiak ◽

K. H. Czarnecka ◽

M. Migdalska-Sęk ◽

E. Nawrot ◽

...

Keyword(s):

Lung Cancer ◽

Pilot Study ◽

Small Cell Lung Cancer ◽

Cancer Patients ◽

Expression Analysis ◽

Cell Lung Cancer ◽

Small Cell ◽

Expression Level ◽

Small Cell Lung ◽

Lung Cancer Patients

Download Full-text

Comprehensive Analysis of Inhibitor of Apoptosis Protein Expression and Prognostic Significance in Non–Small Cell Lung Cancer

Frontiers in Genetics ◽

10.3389/fgene.2021.764270 ◽

2021 ◽

Vol 12 ◽

Author(s):

Jun Liu ◽

Yi Lu ◽

Wenan Huang ◽

Zhibo He

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Prognostic Significance ◽

Small Cell ◽

Expression Level ◽

Mrna Levels ◽

Small Cell Lung ◽

Normal Tissues ◽

Apoptosis Protein

Inhibitors of apoptosis proteins (IAPs) have been associated with tumor development and progression by affecting apoptosis through cell death signaling pathways. To date, eight IAPs (BIRC1–8) have been identified in mammalian cells. However, the role of IAPs in non–small cell lung cancer (NSCLC) development and progression has not been explored in depth. In this study, we used public datasets and bioinformatics tools to compare the expression, prognostic significance, and function of IAPs in NSCLC and its subtypes. Expression of IAPs in cancer and normal tissues and at different stages of NSCLC was compared with gene expression profiling interactive analysis, and their prognostic significance was analyzed with the Kaplan–Meier Plotter database. The correlations among IAPs were analyzed with the STRING database and SPSS19.0. Functional annotation of IAPs was analyzed by Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment on the basis of the DAVID tool. Among patients with lung adenocarcinoma (LUAD), the expression level of BIRC5 was higher than that in normal samples, and the expression of BIRC1 and BIRC5 significantly varied in different stages. Moreover, the BIRC1–3 and BIRC5 mRNA levels were associated with overall survival (OS), and the BIRC1–2 and BIRC5–6 mRNA levels were associated with progression-free survival (PFS). Among patients with lung squamous cell carcinoma (LUSC), the expression level of BIRC1 was lower and that of BIRC5 was higher than those in normal tissues, and BIRC5 expression significantly varied in different stages. BIRC1 expression was associated with OS, whereas BIRC2 and BIRC6 expression was associated with PFS. Enrichment analysis showed that most IAPs are associated with ubiquitin- and apoptosis-related pathways. Collectively, this study suggests BIRC5 as a potential diagnostic and staging marker, BIRC1 as a potential marker of OS, and BIRC2 and BIRC6 as potential PFS markers for patients with NSCLC. These highlight new targets for the early detection, treatment, and management of NSCLC.

Download Full-text

Lung cancer

Oxford Handbook of Cancer Nursing ◽

10.1093/med/9780198569244.003.0035 ◽

2007 ◽

pp. 451-464

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Diagnostic Procedures ◽

Small Cell ◽

Treatment Modalities ◽

Nursing Management ◽

Small Cell Lung ◽

The Usa ◽

The Uk

Introduction 452 Management of non-small cell lung cancer (NSCLC) 456 Management of small cell lung cancer (SCLC) 458 Mesothelioma 460 Nursing management issues 462 Lung cancer is a mainly preventable disease, the main cause being cigarette smoking. It was relatively rare until the 20th century, but is now the leading cause of cancer death in the UK, Europe, and the USA. This is despite changes in treatment modalities, diagnostic procedures, and recent falling smoking rates amongst many sectors of society....

Download Full-text

Evaluation of the relationship between the IL-17A gene expression level and regulatory miRNA-9 in relation to tumor progression in patients with non-small cell lung cancer: a pilot study

Molecular Biology Reports ◽

10.1007/s11033-019-05164-0 ◽

2019 ◽

Vol 47 (1) ◽

pp. 583-592 ◽

Cited By ~ 1

Author(s):

Monika Migdalska-Sęk ◽

Katarzyna Góralska ◽

Sławomir Jabłoński ◽

Jacek Kordiak ◽

Ewa Nawrot ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Tumor Progression ◽

Cell Lung Cancer ◽

Tnm Classification ◽

Small Cell ◽

Expression Level ◽

Small Cell Lung ◽

Increased Risk

Abstract A pro-inflammatory cytokine, IL-17A, is associated with increased risk of developing numerous cancers, including non-small cell lung cancer (NSCLC). IL-17A is a target gene for miR-9. This encouraged us to analyze these two genes in terms of their usefulness as prognostic markers in NSCLC. The expression levels of IL-17A gene and miR-9 was assessed in 26 NSCLC tissue samples and 26 unchanged lung tissue adjacent to lung tumors (control tissue), using qPCR. In both tissue groups, a decreased expression of IL-17A was observed in 100% of samples. Increased expression of miRNA-9 was observed in 92% of tumor samples, and in 100% of control samples. Neither statistical differences in the level of expression IL-17A depending on the patient’s age, gender, smoking status, nor histopathology of the cancer was found. Regarding the presence of nodule metastasis (‘N’ value in TNM classification), significantly lower expression level of IL-17A was observed in cN2 as compared with cN1 group. Additionally, statistically lower IL-17A expression was found in III versus II tumor stage (cAJCC classification). Significant negative correlation between both studied genes was revealed in SCC subgroup. This leads to the conclusion that miRNA-9 can regulate the expression of IL-17A as an IL-17A mRNA antagonistic mediator. Inhibition of proinflammatory action of IL-17A in correlation with tumor progression can be related to various activity of Th17 cells on cancer development according to its immunogenicity, and also may suggest suppressive role of IL-17A in tumor progression. However, because of low number of analyzed samples, further studies on the functional role of IL-17A in development and/or progression NSCLC seem warranted.

Download Full-text